Nicolas Touchot
YOU?
Author Swipe
View article: Epidemiology of acquired hypothalamic obesity following traumatic brain injury and nonspecific hypothalamic microinjury: A nationwide German claims data analysis
Epidemiology of acquired hypothalamic obesity following traumatic brain injury and nonspecific hypothalamic microinjury: A nationwide German claims data analysis Open
Acquired hypothalamic obesity (aHO) is characterized by rapid and persistent weight gain resulting from structural or functional damage to the hypothalamus, typically accompanied by neuroendocrine dysfunction. While aHO is well described i…
View article: Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors Open
View article: Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy
Treatment of patients with tumor/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy Open
View article: Hypothalamic obesity: Epidemiology in rare sellar/suprasellar tumors—A German claims database analysis
Hypothalamic obesity: Epidemiology in rare sellar/suprasellar tumors—A German claims database analysis Open
Hypothalamic obesity (HO) is defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor‐ and/or treatment‐related damage to the hypothalamus. HO epidemiology is poorly understood. We developed a database …
View article: Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries Open
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries hav…
View article: Early Insights from Commercialization of Gene Therapies in Europe
Early Insights from Commercialization of Gene Therapies in Europe Open
After years of research and development, gene therapies are now becoming a commercial reality with several products approved by European regulatory authorities [...]
View article: Feasibility and attractiveness of indication value-based pricing in key EU countries
Feasibility and attractiveness of indication value-based pricing in key EU countries Open
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country…